Heerspink HJL, et al. - Given that change in albuminuria has strong biological plausibility as a surrogate endpoint for progression of chronic kidney disease, researchers assessed the correlation between treatment effects on early changes in albuminuria and treatment effects on clinical endpoints and surrogate endpoints to inform the use of albuminuria as a surrogate endpoint in future randomized controlled trials. In this meta-analysis, 41 eligible treatment comparisons from randomized trials that provided sufficient patient-level data on 29,979 participants were identified. Particularly in patients with high baseline albuminuria, a role for change in albuminuria as a surrogate endpoint for the progression of chronic kidney disease was supported. This association was less certain for patients with low baseline albuminuria levels.